JWH-254
JWH-254 is a synthetic cannabinoid that acts as a potent agonist at the CB1 receptor and CB2 receptor. It is part of the naphthoylindole family of compounds, which are known for their psychoactive properties. JWH-254 was developed by Dr. John W. Huffman and his team at Clemson University as part of research into the structure-activity relationships of cannabinoids.
Chemical Structure and Properties[edit | edit source]
JWH-254 has the chemical formula C19H19NO2 and a molecular weight of 293.36 g/mol. The compound features a naphthoylindole core, which is a common structural motif among synthetic cannabinoids. The presence of a methoxy group on the phenyl ring distinguishes JWH-254 from other related compounds.
Pharmacology[edit | edit source]
JWH-254 acts as a full agonist at both the CB1 and CB2 receptors, which are part of the endocannabinoid system. These receptors are involved in a variety of physiological processes, including pain sensation, mood regulation, and appetite control. The binding affinity of JWH-254 for the CB1 receptor is higher than for the CB2 receptor, which is typical for many synthetic cannabinoids.
Legal Status[edit | edit source]
The legal status of JWH-254 varies by country. In the United States, it is classified as a Schedule I controlled substance under the Controlled Substances Act, meaning it is illegal to manufacture, distribute, or possess. Other countries have similar restrictions due to its potential for abuse and lack of accepted medical use.
Potential Risks and Side Effects[edit | edit source]
As with other synthetic cannabinoids, JWH-254 can produce a range of side effects, including anxiety, paranoia, tachycardia, and hallucinations. The long-term health effects of JWH-254 use are not well understood, but there is concern about its potential to cause addiction and other adverse health outcomes.
Research and Applications[edit | edit source]
JWH-254, like other synthetic cannabinoids, has been used in scientific research to better understand the endocannabinoid system and the effects of cannabinoid receptor activation. However, due to its legal status and potential for abuse, research is limited and tightly regulated.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
